What happens to your weight when you stop taking semaglutide?
The strongest evidence comes from a large, randomized controlled trial called STEP 4, which followed 803 people who had already lost an average of 10.6% of their body weight during a 20-week run-in on semaglutide [1]. Half were randomly assigned to continue semaglutide for another 48 weeks, and the other half were switched to a placebo. Those who stayed on semaglutide lost an additional 7.9% of their body weight, while those who stopped regained 6.9% — a net difference of nearly 15 percentage points. In plain terms, stopping the drug caused most of the lost weight to come back within a year.
A separate analysis of the STEP 1 trial found that after discontinuation, 1,961 participants regained an average of 11.6% of their lost weight [4]. That means roughly two-thirds of the weight they had shed returned. A systematic review of GLP-1 agonists for obesity also explicitly names weight regain after stopping as a major challenge [3]. Together, these studies converge on the same conclusion: the weight-loss effects of semaglutide are not durable once treatment ends.
Does taking semaglutide for a longer time make the weight loss last after you stop?
A recent retrospective study of electronic health records specifically tested whether a longer course of semaglutide leads to more durable weight loss after stopping [5]. It found no such effect. In fact, patients treated for longer periods tended to regain more weight after discontinuation, though this trend was not statistically significant. The study's authors concluded that they could not identify any duration of therapy that was associated with lasting weight loss. This suggests that the drug's effect is tied to ongoing use, not to how long you have been on it.
This finding aligns with the STEP 4 trial, where even after 20 weeks of treatment, stopping led to rapid regain [1]. The animal study on Alzheimer's disease offers a different angle: it found that semaglutide had some prolonged protective effects on brain cells 60 days after stopping, such as reducing inflammation and tau protein buildup [2]. However, this was in rats, not humans, and it did not stop the overall neurodegenerative process. For weight loss specifically, the human data consistently show that benefits fade quickly after discontinuation.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2021 to 2026, 4 from 2024 or later, 1 in Q1 journals, collectively cited 1,094 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 58 papers retrieved from a database of over 500 million.
Sources used in this answer
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
In a large randomized controlled trial (STEP 4), 803 adults who had lost 10.6% on semaglutide were randomized: those who continued lost another 7.9% over 48 weeks, while those switched to placebo regained 6.9% — a 14.8 percentage-point difference, showing weight loss is not maintained after stopping.
Impact of Semaglutide on Hippocampal Injury in a Streptozotocin-Induced Model of Alzheimer’s Disease
In a rat model of Alzheimer's disease, a 5-week course of semaglutide showed some prolonged neuroprotective effects (e.g., reduced brain inflammation and tau protein) 60 days after stopping, but did not halt overall neurodegeneration — suggesting limited durability in a non-weight-loss context.
GLP-1 ANALOGUES IN OBESITY THERAPY: CURRENT EVIDENCE AND FUTURE DIRECTIONS – A SYSTEMATIC REVIEW
A systematic review of GLP-1 agonists for obesity (including semaglutide) concluded that weight regain after treatment discontinuation is a major challenge, alongside high costs and the need for long-term safety data.
Semaglutide and weight loss – a concern for diabetics and pharmaceuticals
Analysis of the STEP 1 trial (1,961 participants) found that after stopping semaglutide, people regained 11.6% of their lost weight — roughly two-thirds of what they had lost — and cardio-metabolic improvements reversed.
Glucagon-like peptide-1 (GLP-1) receptor agonist therapy duration vs durability of weight loss
A retrospective cohort study of electronic health records found no association between longer semaglutide treatment duration and more durable weight loss after stopping; if anything, longer use trended toward greater regain.